The $10 million molecule: Juno Therapeutics’ acquisition of RedoxTherapies could improve cancer treatment by Monica Nickelsburg on July 15, 2016July 15, 2016 at 9:14 am Seattle-based Juno Therapeutics has acquired RedoxTherapies for $10 million, to secure exclusive rights to a molecule that may provide a new cancer treatment. The molecule, called vipadenant, may help the immune… Read More